Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Amifostine

Amifostine: 1 brand, 2 generics; first approved Dec 08, 1995; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 2 ANDA applications approved.

Brands (NDA)
1
Generics (ANDA)
2
Listed patents
0
Presentations
4

Brand (NDA) products

Originator applications
  • ETHYOLRLDRS
    NDA 02022119952 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    500MG/VIALINJECTABLEINJECTIONRx
    375MG/VIALINJECTABLEINJECTIONDiscontinued

Generic (ANDA) products (2)

Abbreviated applications
  • AMIFOSTINE
    ANDA 2043632017
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    500MG/VIALINJECTABLEINJECTIONDiscontinued
  • AMIFOSTINE
    ANDA 0771262008
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    500MG/VIALINJECTABLEINJECTIONDiscontinued

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
31 yr 2 mo ago
Most recent approval
9 yr 3 mo ago

Approvals span 1995–2017 across 3 FDA applications.

Brand (NDA) 133%
Generic (ANDA) 267%

Amifostine: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.